ABCL - LCID SDC and ABCL among pre market gainers
Corvus Pharmaceuticals (NASDAQ:CRVS) +56%. Innate Pharma (NASDAQ:IPHA) +32% Monalizumab data from COAST trial presented at ESMO Congress 2021 Surface Oncology (NASDAQ:SURF) +14%. BeiGene (NASDAQ:BGNE) +13% on positive DKN-01 + tislelizumab data in gastroesophageal cancer AbCellera Biologics (NASDAQ:ABCL) +13%. Gritstone bio. (NASDAQ:GRTS) +8% dosing underway in Gritstone's Phase 2 SLATE v2 trial in patients with solid tumors Achieve Life Sciences (NASDAQ:ACHV) +8%. SmileDirectClub (NASDAQ:SDC) +8%. Vascular Biogenics (NASDAQ:VBLT) +7% on go with Phase 3 VB-111 study in ovarian cancer after DSMC recommendation Code Chain New Continent (NASDAQ:CCNC) +6%. Agenus (NASDAQ:AGEN) +6% balstilimab + zalifrelimab combo shows promising overall results in cervical cancer patients Arcus Biosciences (NYSE:RCUS) +6%. Enveric Biosciences (NASDAQ:ENVB) +7% announces closing of MagicMed Industries acquisition Lucid Group (NASDAQ:LCID) +6%. Berkeley Lights (NASDAQ:BLI) +5%. Worksport (OTCQB:WKSP) +5%. Invesco (NYSE:IVZ) +5% in merger talks with State Street asset management business - WSJ
For further details see:
LCID, SDC and ABCL among pre market gainers